IVT Price sensitive 31 Jan 2025, 12:04 PM

Quarterly Activities/Appendix 4C Cash Flow Report

Inventis Ltd

Inventis Ltd reports Q2 results, plans for growth

Key points

  • Confirmed Opentec orders > $5.7M in Q2 expected to settle in Q3
  • Raised $2.5M USD for Hazavoid Tx LLC, a debt-free USA subsidiary
  • Developing recurring revenue funding facility and subscription model for Hazavoid

Full summary

Inventis Ltd has released its quarterly activities and cash flow report for the period ending 30th December 2024. Key highlights include: Confirmed Opentec orders exceeding $5.7M in Q2, expected to settle in Q3; Initiated a $2.5M USD capital raise for the debt-free Hazavoid Tx LLC subsidiary in the USA, which has built a pipeline of over AUD$3.4M in direct open quotes; Developed a recurring revenue funding facility for Hazavoid's 'Lease to Buy' model and planning for a new Hazavoid mobile app subscription service; Received an order confirmation for the Hazavoid project in Palawan, Philippines, and are pressing for the National Risk Reduction Management Centre to adopt Hazavoid more widely; Secured a new exclusive agency agreement with Varley Group to sell custom emergency vehicles in the Philippines, targeting over $60M in opportunities; The Electronic Circuit Designs division is finalizing new corporate IP and seeking to expand into the US and Southeast Asian markets; The Furniture Division has seen a slowdown in Q2 but is building a $8M pipeline, expecting a recovery in Q4; The company is exploring various capital raising options, including a $2.5M USD equity placement in Hazavoid Tx LLC and potential $8-10M investment to fuel international growth.

Guidance

The company expects to see a recovery in Technology Division sales in Q3 and Q4 of the financial year, with large invoicing due in February 2025. The Hazavoid mobile app subscription service is projected to earn up to $4 Million per annum by 2029.

Outlook

Inventis is focused on aligning costs with income, with headcount reductions and factory relocations expected to deliver $574K in future cost savings. The company is pursuing various capital raising options to fuel the growth of its Hazavoid and other technology-driven business units, including a $2.5M USD equity placement and potential $8-10M investment.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in